NRX Pharmaceuticals Inc (NRXP) — Cash Flow-to-Debt Ratio
NRX Pharmaceuticals Inc (NRXP) has a Cash Flow-to-Debt Ratio of -0.07x as of September 2025, meaning its operating cash flow of $-2.89 Million could theoretically repay 0% of its total liabilities ($40.75 Million) in one year. See NRX Pharmaceuticals Inc (NRXP) working capital ratio to evaluate short-term liquidity relative to the company's equity base.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
NRX Pharmaceuticals Inc Cash Flow-to-Debt Ratio (2017–2024)
Historical debt coverage capacity for NRX Pharmaceuticals Inc across 8 annual periods. Also explore NRX Pharmaceuticals Inc equity growth rate to track the company's year-over-year net asset growth rate.
Annual Cash Flow-to-Debt Ratio for NRX Pharmaceuticals Inc (2017–2024)
Year-by-year debt coverage analysis for NRX Pharmaceuticals Inc. For market capitalisation and broader financial context, see NRX Pharmaceuticals Inc market cap and net worth.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | -0.40x | $-10.64 Million | $26.87 Million | ▲ +65.2% |
| 2023 | -1.14x | $-21.66 Million | $19.05 Million | ▲ +47.4% |
| 2022 | -2.16x | $-39.76 Million | $18.41 Million | ▲ +31.7% |
| 2021 | -3.16x | $-37.70 Million | $11.92 Million | ▼ -6421.5% |
| 2020 | -0.05x | $-2.27 Million | $46.71 Million | ▲ +84.3% |
| 2019 | -0.31x | $-792.73K | $2.57 Million | ▲ +18.2% |
| 2018 | -0.38x | $-473.19K | $1.26 Million | ▲ +74.2% |
| 2017 | -1.46x | $-135.81K | $93.17K | — |